Figure 4.

OS with respect to the dose of CA in the HDCA/CY/TBI group. OS was calculated using the Kaplan-Meier method, and prognosis was compared between the 2 major dosages of HDCA (ie, 12 vs 8 g/m²). (A) OS was higher in the higher-dose HDCA group (12 g/m²) than in the lower-dose group (8 g/m²) (68.3% vs 61.6% at 1 year; 58.3% vs 50.5% at 3 years); this difference was significant (P = .04) after being adjusted for other confounding factors such as patient sex, age, PS, CMV serostatus, disease risk, pretransplant therapy period, HLA mismatch, and ABO mismatch. In the subgroup analyses according to disease risk, (B) higher-dose HDCA significantly showed the better OS in the high-risk group, but (C) not in the standard-risk group.